Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TriSalus Life Sciences (TLSI) Preferred Shares Issued (2022 - 2023)

TriSalus Life Sciences posted quarterly Preferred Shares Issued of $5000.0 for Q3 2023, down 99.92% on a QoQ basis from $6.0 million in Q2 2023.

TriSalus Life Sciences (TLSI) has 2 years of Preferred Shares Issued data on file, last reported at $5000.0 in Q3 2023.

  • For the quarter ending Q3 2023, Preferred Shares Issued changed N/A year-over-year to $5000.0; the trailing twelve-month figure through Jun 2024 stood at $5000.0 (changed N/A YoY), and the FY2023 full-year result was $9.2 million, down 31.93% from the prior year.
  • Preferred Shares Issued for Q3 2023 stood at $5000.0, down from $6.0 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $10.0 million in Q4 2022 and bottomed at $5000.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 TriSalus Life Sciences 187.09 Mn 130.54 Mn 7.67 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2023 5,000.00
Sep 30, 2023 5,000.00
Jun 30, 2023 6.00 Mn
Jun 30, 2023 6.00 Mn
Mar 31, 2023 3.18 Mn
Mar 31, 2023 3.18 Mn
Dec 31, 2022 10.00 Mn
Dec 31, 2022 10.00 Mn